Executive Summary
The Oral anti diabetes drug was valued at USD 25.6 Billion in the year 2018. Over the recent years, oral anti-diabetes drug has been witnessing considerable growth on the back of rising incidences of diabetes, growing geriatric population, growing government initiatives, and continuous research and development conducted by pharmaceutical manufacturers. In addition, growing sedentary lifestyle, presence of diabetes medicines in the Essential drug List of the nations and wide insurance coverage for diabetes drugs have contributed to the growth rate of Oral anti-diabetes drugs. These factors are anticipated to provide higher momentum to the market growth in the forecast period. However, preferred use of insulin over oral anti diabetes drugs and the complications associated with the drugs has been hindering the market growth.
Among all the types of oral anti-diabetes drugs that includes Biguanides, Sulfonylurease, DPP-4 inhibitor, SGL2 inhibitor and Thiazolidinedione, Biguanides holds the highest market share in the Oral Anti-diabetic drug Market owing to its proven benefits in the treatment of diabetes mellitus.
Among the regions, North America Oral Anti-diabetic drug Market will continue to be the largest market in the forecast period, majorly driven by favourable government reimbursement policies in addition to high healthcare awareness. Countries such as India, China, Brazil are a lucrative market for Oral Anti-diabetic drugs Market.
Scope of the Report
Global Oral Anti-Diabetes Drugs Market (Actual Period: 2014-2018, Forecast Period: 2019-2024)
Oral Anti-Diabetes Drugs Market Size, Growth, Forecast
Analysis by Type: Biguanides, Sulfonylurease, DPP-4 inhibitor, SGL2 inhibitor, Thiazolidinediones, Others
Regional Oral Anti-Diabetes Drugs Market - North America, Europe, APAC, ROW (Actual Period: 2014-2018, Forecast Period: 2019-2024)
Oral Anti-Diabetes Drugs Market Size, Growth, Forecast
Analysis by Type: Biguanides, Sulfonylurease, DPP-4 inhibitor, SGL2 inhibitor, Thiazolidinediones, Others
Country Analysis - U.S. Canada, U.K., Germany, France, Italy, India, Japan, China, Brazil (Actual Period: 2014-2018, Forecast Period: 2019-2024)
Oral Anti-Diabetes Drugs Market Size, Growth, Forecast
Analysis by Type: Biguanides, Sulfonylurease, DPP-4 inhibitor, SGL2 inhibitor, Thiazolidinediones, Others
Company Analysis Novartis, Pfizer, Sanofi, Merck & Co., AstraZeneca, Janssen Pharmaceutical, Boehringer Ingelheim, Eli Lilly, Takeda Pharmaceutical.
Other Report Highlights
Competitive Landscape Sales, Segments, Market Share
Leading Companies
Non generic drug analysis
Market Dynamics Drivers and Restraints.
Market Trends
Porter Five Forces Analysis.
SWOT Analysis.
